Clinical Trial Update: To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH [Phase 2]

View source ↗

Summary

This clinical trial update notes a Phase 2 study evaluating FCN-159 in pediatric patients with refractory or recurrent Langerhans cell histiocytosis (LCH) to as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• FCN-159

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Langerhans Cell Histiocytosis, LCH | Phase 2 | Status: RECRUITING